We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bayer to Acquire Visible Genetics, Inc.

By HospiMedica staff writers
Posted on 12 Aug 2002
In a move that will expand its portfolio of molecular diagnostic tests, an agreement has been announced by Bayer Corp., Diagnostics Division (Tarrytown, NY), to acquire Visible Genetics Inc.(VGI, Toronto, Canada) in a cash deal valued at US$61.4 million.

As part of the transaction, Bayer Diagnostics will acquire the Trugene HIV-1 Genotyping Assay, the only HIV sequencing resistance test available in the United States that is approved by the US Food and Drug Administration (FDA). More...
Combined with Bayer's Versant HIV and hepatitis C virus (HCV) viral nucleic acid tests, these will enable Bayer to have a leading position in the nucleic acid diagnostic (NAD) segment of the professional laboratory market. The acquisition will also include all VGI sequencing assays, such as hepatitis assays, currently in development.

"This acquisition is another milestone in our ongoing strategy to expand our infection disease portfolio that began with our acquisition of Chiron Diagnostics in 1998,” said Rolf Classon, president of Bayer Business Group Diagnostics. "It also supports our strategy to bring to market molecular diagnostic tests that assist the physician in the diagnosis and monitoring of disease and treatment regimens.”





Related Links:
Bayer Diagnostics
Visible Genetics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Electrolyte Analyzer
BKE-B
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.